Complex intensive treatment shows promise against a complex aggressive disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Neuromyelitis optica (NMO) spectrum disorder (NMOSD) comprises a group of neuroinflammatory disorders characteristically affecting the optic nerves and the spinal cord. Previously known as Devic disease, NMO was considered a variant of multiple sclerosis (MS) until the discovery of anti-aquaporin 4 immunoglobulin G (AQP4-IgG) identified NMO as a separate disease.1 Over the following decade, studies of NMOSD have described with increasing precision the clinical,2 radiologic,3 and neuropathologic4 features.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 785
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis opticaRichard K. Burt, Roumen Balabanov, Xiaoqiang Han et al.Neurology, October 02, 2019 -
Research Article
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple SclerosisA Real-world Case SeriesRichard S. Nicholas, Elijah E. Rhone, Alice Mariottini et al.Neurology, July 12, 2021 -
Article
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple SclerosisPeter Alping, Joachim Burman, Jan Lycke et al.Neurology, January 29, 2021 -
In Focus
Spotlight on the October 29 issueRobert A. Gross et al.Neurology, October 28, 2019